Venom-inspired somatostatin receptor 4 (SSTR4) agonists as new drug leads for peripheral pain conditions

• Published in: bioRxiv : the preprint server for biology
• Main Authors: Bjørn-Yoshimoto, Walden E, Ramiro, Iris Bea L, Koch, Thomas Lund, Engholm, Ebbe, Yeung, Ho Yan, Sørensen, Kasper K, Goddard, Carolyn M, Jensen, Kathrine L, Smith, Nicholas A, Martin, Laurent F, Smith, Brian J, Madsen, Kenneth L, Jensen, Knud J, Patwardhan, Amol, Safavi-Hemami, Helena
• Format: Journal Article
• Language: English
• Published: United States 30.04.2024
• DOI: 10.1101/2024.04.29.591104

Persistent pain affects one in five people worldwide, often with severely debilitating consequences. Current treatment options, which can be effective for mild or acute pain, are ill-suited for moderate-to-severe persistent pain, resulting in an urgent need for new therapeutics. In recent years, the somatostatin receptor 4 (SSTR ), which is expressed in sensory neurons of the peripheral nervous system, has emerged as a promising target for pain relief. However, the presence of several closely related receptors with similar ligand-binding surfaces complicates the design of receptor-specific agonists. In this study, we report the discovery of a potent and selective SSTR peptide, consomatin Fj1, derived from extensive venom gene datasets from marine cone snails. Consomatin Fj1 is a mimetic of the endogenous hormone somatostatin and contains a minimized binding motif that provides stability and drives peptide selectivity. Peripheral administration of synthetic consomatin Fj1 provided analgesia in mouse models of postoperative and neuropathic pain. Using structure-activity studies, we designed and functionally evaluated several Fj1 analogs, resulting in compounds with improved potency and selectivity. Our findings present a novel avenue for addressing persistent pain through the design of venom-inspired SSTR -selective pain therapeutics. Venom peptides from predatory marine mollusks provide new leads for treating peripheral pain conditions through a non-opioid target.